Short Interest in ReWalk Robotics Ltd. (NASDAQ:LFWD) Increases By 21.4%

ReWalk Robotics Ltd. (NASDAQ:LFWD) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 222,600 shares, an increase of 21.4% from the December 15th total of 183,400 shares. Based on an average daily trading volume, of 214,800 shares, the days-to-cover ratio is currently 1.0 days. Approximately 3.0% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of ReWalk Robotics in a research report on Wednesday, November 13th.

ReWalk Robotics Stock Performance

LFWD stock opened at $1.64 on Friday. The company’s fifty day moving average price is $1.88 and its 200-day moving average price is $2.79. ReWalk Robotics has a one year low of $1.41 and a one year high of $7.84. The company has a market capitalization of $14.45 million, a PE ratio of -0.66 and a beta of 2.08.

ReWalk Robotics (NASDAQ:LFWD) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.08). ReWalk Robotics had a negative net margin of 77.21% and a negative return on equity of 43.02%. The company had revenue of $6.13 million for the quarter, compared to the consensus estimate of $8.38 million. During the same period last year, the company earned ($0.56) EPS. On average, research analysts predict that ReWalk Robotics will post -1.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Michael Swinford bought 21,622 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was bought at an average price of $2.03 per share, with a total value of $43,892.66. Following the acquisition, the director now owns 65,040 shares of the company’s stock, valued at approximately $132,031.20. This represents a 49.80 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Global Fund Lp Lind II sold 381,676 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $3.36, for a total value of $1,282,431.36. Following the completion of the sale, the insider now owns 1,049,430 shares of the company’s stock, valued at $3,526,084.80. The trade was a 26.67 % decrease in their position. The disclosure for this sale can be found here. Insiders purchased a total of 61,000 shares of company stock worth $115,279 over the last quarter. 2.50% of the stock is currently owned by corporate insiders.

Institutional Trading of ReWalk Robotics

A hedge fund recently bought a new stake in ReWalk Robotics stock. Dimensional Fund Advisors LP bought a new stake in shares of ReWalk Robotics Ltd. (NASDAQ:LFWD) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned about 0.16% of ReWalk Robotics as of its most recent filing with the Securities and Exchange Commission. 26.76% of the stock is owned by institutional investors.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.